The inclusion in these trials is usually restricted to HPV-negative HNSCC and sometimes to patients whose tumors harbor alterations in the genes involved in cell cycle regulation (amplification of CCND1 in NCT03088059, intact Rb and genetic alterations in CDK4/CDK6 pathway in NCT03356587). The gene discussed is CCND1; the disease is head and neck squamous cell carcinoma.